Story perspectives

Compass Pathways' COMP360 Shows Promise for Severe Depression

2/18/2026

Summary

Story summary

Compass Pathways announced results from two Phase 3 trials of COMP360 for severe depression.
The trials showed a statistically significant reduction in depression symptoms, with a 3.8-point decrease on the Montgomery-Åsberg Depression Rating Scale (MADRS) after two doses.
Compass Pathways plans a rolling submission with the U.S. Food and Drug Administration (FDA), aiming for completion in Q4 2026.
There were reports of suicidal ideation, but safety profile remained consistent with prior studies.

1 of 1

Story summary

Compass Pathways announced results from two Phase 3 trials of COMP360 for severe depression.
The trials showed a statistically significant reduction in depression symptoms, with a 3.8-point decrease on the Montgomery-Åsberg Depression Rating Scale (MADRS) after two doses.
Compass Pathways plans a rolling submission with the U.S. Food and Drug Administration (FDA), aiming for completion in Q4 2026.
There were reports of suicidal ideation, but safety profile remained consistent with prior studies.